Rezolute (NASDAQ: RZLT) — Company Overview, News & Financial Data
Rezolute develops novel therapies for endocrinology and metabolism disorders, addressing significant unmet medical needs.
Rezolute
Rezolute (NASDAQ:RZLT) specializes in developing novel therapies for diseases with significant unmet medical needs, focusing primarily on endocrinology and metabolism disorders. Their key projects aim to advance treatments for conditions such as congenital hyperinsulinism and chronic diabetes complications, striving to bring innovative solutions to patients worldwide. The company's objectives are centered around pushing the boundaries of medical science to improve patient care and outcomes, leveraging cutting-edge research and development to bring their groundbreaking therapies from the lab to the clinic. With a commitment to excellence and innovation, Rezolute continues to make significant strides in addressing some of the most challenging health issues facing people today.
Snapshot
Operations
Products and/or services of Rezolute
- RZ402 is a sustained delivery microdose therapy aimed at treating diabetic macular edema.
- RZ358, an IV-administered human monoclonal antibody designed for the treatment of Congenital Hyperinsulinism by balancing insulin levels.
- The company engages in strategic collaborations to enhance its pipeline, leveraging biotechnological advancements for rare and serious chronic diseases.
- A proprietary technology platform that focuses on the development of long-acting injectables for precision dosing and improved patient compliance.
Rezolute executive team
- Nevan Charles ElamFounder, CEO & Acting Chairman of the Board
- Daron G. EvansChief Financial & Business Officer
- Brian Kenneth RobertsChief Medical Officer
- Sunil KarnawatChief Commercial Officer
- Michael R. DeperroSenior VP & Head of Operations
- Davelyn Eaves HoodDirector and Head of Scientific & Patient Affairs
- Melissa QuinnSenior Director of People and Culture
- Chris MilksVP & Head of Finance
- Robyn SweinhartVP & Head of Quality
- Erin O'BoyleSenior VP & Head of Clinical Operations